Biotech News

Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsConference / presentation

WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present new data from its clinical

Related news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

Stock data

Close
25.08 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States